Subtype-specific GABA transporter antagonists synergistically modulate phasic and tonic GABAA conductances in rat neocortex

J Neurophysiol. 2005 Sep;94(3):2073-85. doi: 10.1152/jn.00520.2005. Epub 2005 Jun 29.

Abstract

GABAergic inhibition in the brain can be classified as either phasic or tonic. gamma-Aminobutyric acid (GABA) uptake by GABA transporters (GATs) can limit the time course of phasic currents arising from endogenous and exogenous GABA, as well as decrease a tonically active GABA current. GABA transporter subtypes 1 and 3 (GAT-1 and GAT-3) are the most heavily expressed of the four known GAT subtypes. The role of GATs in shaping GABA currents in the neocortex has not been explored. We obtained patch-clamp recordings from layer II/III pyramidal cells and layer I interneurons in rat sensorimotor cortex. We found that selective GAT-1 inhibition with NO711 decreased the amplitude and increased the decay time of evoked inhibitory postsynaptic currents (IPSCs) but had no effect on the tonic current or spontaneous IPSCs (sIPSCs). GAT-2/3 inhibition with SNAP-5114 had no effect on IPSCs or the tonic current. Coapplication of NO711 and SNAP-5114 substantially increased tonic currents and synergistically decreased IPSC amplitudes and increased IPSC decay times. sIPSCs were not resolvable with coapplication of NO711 and SNAP-5114. The effects of the nonselective GAT antagonist nipecotic acid were similar to those of NO711 and SNAP-5114 together. We conclude that synaptic GABA levels in neocortical neurons are controlled primarily by GAT-1, but that GAT-1 and GAT-2/3 work together extrasynaptically to limit tonic currents. Inhibition of any one GAT subtype does not increase the tonic current, presumably as a result of increased activity of the remaining transporters. Thus neocortical GAT-1 and GAT-2/3 have distinct but overlapping roles in modulating GABA conductances.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 6-Cyano-7-nitroquinoxaline-2,3-dione / pharmacology
  • Analysis of Variance
  • Animals
  • Animals, Newborn
  • Anisoles / pharmacology
  • Bicuculline / pharmacology
  • Dose-Response Relationship, Drug
  • Dose-Response Relationship, Radiation
  • Drug Synergism
  • Electric Stimulation / methods
  • GABA Agonists / pharmacology
  • GABA Antagonists / pharmacology
  • GABA Plasma Membrane Transport Proteins
  • In Vitro Techniques
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Membrane Potentials / radiation effects
  • Membrane Transport Modulators*
  • Membrane Transport Proteins / antagonists & inhibitors*
  • Membrane Transport Proteins / classification
  • Models, Neurological
  • Muscimol / pharmacology
  • Neocortex / cytology
  • Neocortex / physiology*
  • Neural Inhibition / drug effects
  • Neural Inhibition / physiology
  • Neural Inhibition / radiation effects
  • Neurons / classification
  • Neurons / drug effects
  • Neurons / physiology
  • Neurons / radiation effects
  • Neurotransmitter Uptake Inhibitors / classification
  • Neurotransmitter Uptake Inhibitors / pharmacology*
  • Nipecotic Acids / pharmacology
  • Oximes / pharmacology
  • Patch-Clamp Techniques / methods
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, GABA-A / physiology*
  • Time Factors
  • gamma-Aminobutyric Acid / metabolism*

Substances

  • 1-(2-(tris(4-methoxyphenyl)methoxy)ethyl)-3-piperidinecarboxylic acid
  • Anisoles
  • GABA Agonists
  • GABA Antagonists
  • GABA Plasma Membrane Transport Proteins
  • Membrane Transport Modulators
  • Membrane Transport Proteins
  • Neurotransmitter Uptake Inhibitors
  • Nipecotic Acids
  • Oximes
  • Receptors, GABA-A
  • Slc6a1 protein, rat
  • NNC 711
  • nipecotic acid
  • Muscimol
  • gamma-Aminobutyric Acid
  • 6-Cyano-7-nitroquinoxaline-2,3-dione
  • Bicuculline